ViewPoint Therapeutics

OverviewSuggest Edit

ViewPoint Therapeutics is a biotechnology company which develops treatments for diseases of protein misfolding, including cataracts. To address the need for new methods to treat cataracts and presbyopia, the Company is developing crystallin stabilizers, such as VP1-001, a molecule designed to stabilize the functional form of the crucial human lens protein alpha-crystallin against accumulated damage.

TypePrivate
Founded2014
Websiteviewpointtherapeutics.com

Latest Updates

Employees (est.) (Jan 2020)15(-6%)

Key People/Management at ViewPoint Therapeutics

Leah Makley

Leah Makley

President and Chief Executive Officer
Brian Connolly

Brian Connolly

Senior Director of Project Management
Show more

ViewPoint Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2014

ViewPoint Therapeutics total Funding

$39 m

ViewPoint Therapeutics latest funding size

$35 m

Time since last funding

2 years ago

ViewPoint Therapeutics investors

ViewPoint Therapeutics's latest funding round in March 2018 was reported to be $35 m. In total, ViewPoint Therapeutics has raised $39 m
Show all financial metrics

ViewPoint Therapeutics Online and Social Media Presence

Embed Graph

ViewPoint Therapeutics Frequently Asked Questions

  • When was ViewPoint Therapeutics founded?

    ViewPoint Therapeutics was founded in 2014.

  • Who are ViewPoint Therapeutics key executives?

    ViewPoint Therapeutics's key executives are Leah Makley and Brian Connolly.

  • How many employees does ViewPoint Therapeutics have?

    ViewPoint Therapeutics has 15 employees.

  • Who are ViewPoint Therapeutics competitors?

    Competitors of ViewPoint Therapeutics include Nordic Nanovector, NeuroVive Pharmaceutical and Y-mAbs Therapeutics.